Added to YB: 2026-10-07
Pitch date: 2026-10-02
340450.KQ [neutral]
GC Genome Corporation
-6.31%
current return
Author Info
No bio for this author
Company Info
GC Genome Corporation operates as a clinical genome analysis company in South Korea. It offers hereditary cancer, tissue and liquid biopsy genetic, blood cancer, and homologous recombination deficiency tests under the Green Plan names; Guardant360, a blood genetic profiling test; Guardant Reveal, a liquid biopsy microscopic residual disease detection and recurrence monitoring test; and genetic rare disease testing services for chromosomal microarray, targeted exome sequencing, whole exome sequencing, and diagnostic genome sequencing.
Market Cap
KRW 210.0B
Pitch Price
KRW 9.0K
Price Target
N/A
Dividend
N/A
EV/EBITDA
36.13
P/E
38.64
EV/Sales
5.26
Sector
Biotechnology
Category
N/A
The U.S. AI-Biotech Rally: Why Proteina, GC Genome, and ST Pharm Need Separate Cases in Korea - GC Genome Corporation
340450.KQ (monitor): GC Genome has an established hospital/testing network and a profitable testing business; ai-CANCERCH detects cancer signals in cell-free blood DNA, serving a different purpose from Natera’s tumor-informed Signatera MRD test. H1 revenue rose ~7.5% to KRW 15.72B, with KRW 570M operating profit and KRW 3.03B positive operating cash flow; at ~7x prior-year revenue, key checks are paid volumes/net receipts, Japanese repeat orders and PANC-CERCH’s U.S. clinical, regulatory and commercial terms.
Read full article (1 min)